Samsung Biologics announced on Monday that it has made an all-cash offer of $1.8 billion to acquire PolyPeptide Group, a company specializing in peptide-based active pharmaceutical ingredients.
Peter Wilden, Chairman of the Board of Directors of PolyPeptide, said: “PolyPeptide was built on the dedication of our employees, deep scientific expertise and strong customer focus. After a comprehensive review of strategic options, the Board is convinced that Samsung Biologics’ offer is compelling for our shareholders, delivering an attractive cash price and immediate, certain value today. At the same time, it represents a transformational opportunity to accelerate our strategic ambitions at a scale we could not reach alone – creating a stronger global partner for customers and a platform uniquely positioned to lead the next phase of growth in peptide-based therapeutics.”
“This acquisition reinforces our long-term growth strategy by not only broadening our service portfolio with modality expansion into peptides including GLP-1, but by also boosting our geographic reach and proximity further within the US, Europe, and India,” said John Rim, Chairman of the Board of Directors and CEO of Samsung Biologics. “We highly value PolyPeptide’s world class employees, industry leading capabilities, and global operational footprint, and look forward to leveraging the complementary strengths of PolyPeptide and Samsung Biologics in our continued growth supporting clients as the CDMO of choice for decades to come.”
Samsung Biologics plans to diversify its portfolio by entering the peptide therapeutics market, a rapidly growing segment driven by increased demand for obesity treatments.
Peptide therapeutics are medications composed of short amino acid chains, such as GLP-1 drugs used for obesity and diabetes that emulate a natural hormone to decrease appetite and control blood sugar.
The transaction is anticipated to close by the end of 2026.
Samsung Biologics shares slipped 1.3% following the announcement.
By CEO NA Editorial Staff
